|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.086 USD | +0.23% |
|
+50.88% | -6.52% |
| Mar. 29 | Inhibitor Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Introducing Inhibitor Therapeutics, Inc. Announces Scientific Advisory Board | CI |
Inhibitor Therapeutics, Inc. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net income was USD 12.11 million compared to net loss of USD 0.298632 million a year ago. Basic earnings per share from continuing operations was USD 0.03.
Diluted earnings per share from continuing operations was USD 0.03.
| 1st Jan change | Capi. | |
|---|---|---|
| -6.52% | 14.76M | |
| -2.63% | 103B | |
| +1.62% | 95.28B | |
| +1.46% | 22.15B | |
| -16.67% | 21.02B | |
| -8.58% | 18.15B | |
| -38.74% | 16.73B | |
| -13.21% | 16.05B | |
| +5.41% | 13.68B | |
| +33.57% | 12.17B |
INHIBITOR THERAPEUTICS, INC. 
